The primary construct, TAG GB4, is targeted specifically against WHO Grade II-IV Astrocytomas
The construct has been modified to specifically bind to other primary brain tumors, TAG EP3 and TAG MB1, both of which have been designated orphan disease status
The disease spectrum has been further expanded towards both chronic and malignant diseases of the integuement.
A prophylactic variant, TAG SC1, is targeted against a common, global neoplasm has been developed. This variant is designed to supplement existing products for topical application